[1]孟召伟,董峰,谭建.乳腺癌的雌激素受体显像[J].国际放射医学核医学杂志,2007,31(3):157-159.
　MENG Zhao-wei,DONG Feng,TAN Jian.Estrogen receptor imaging in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):157-159.
点击复制

乳腺癌的雌激素受体显像(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第3期
页码:
157-159
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Estrogen receptor imaging in breast cancer
作者:
孟召伟;  董峰;  谭建
300052 天津, 天津医科大学总医院核医学科
Author(s):
MENG Zhao-wei;  DONG Feng;  TAN Jian
Department of Nuclear Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China
关键词:
乳腺肿瘤; 受体; 雌激素; 雌二醇; 氟脱氧葡萄糖F18
Keywords:
Breast neoplasms; Receptors; estrogen; Estradiol; Fluorodeoxyglucose F18
分类号:
R817.4
摘要:
雌激素对乳腺癌的作用是通过与雌激素受体(ER)的结合来实现的,已发现ER有两个亚型.18F-16α-氟雌二醇(18F-FES)核素受体显像可显示出乳腺癌病灶有生物活性的ER,若乳腺癌原发灶或转移灶对18F-FES标准化摄取值(SUV)高,则内分泌治疗的有效预测值升高;若在他莫西芬治疗前和治疗后7~10 d分别行18F-氟脱氧葡萄糖(18F-FDG)PET和18F-FES PET双核素显像,对于有效组治疗后18F-FES PET的SUV下降,18F-FDG PET的SUV升高.
Abstract:
Estrogen plays an important role in breast cancer by binding with estrogen receptor(ER).There are two ER subtypes(α and β).16α-18F-fluoroestradiol (18F-FES) imaging can detect biologically active ER in breast cancer. This nuclear imaging technique can show the effectiveness of antiestrogen treatment and has deep implications on prognosis of breast cancer. Quantitative 18F-FES uptake and antiestrogen treatment response are significantly associated; baseline 18F-FES imaging demonstrated that tumors in the patients who responded to tamoxifen had a higher mean standard uptake value for 18F-FES than the nonresponders. After tamoxifen treatment,the mean tumor 18F-fluoroestradio uptake decreased consistently with binding of tamoxifen and its bioactive metabolites to ERs. While in the metabolic flare responders, the tumor 18F-fluorodeoxyglucose uptake increased 7 to 10 days after tamoxifen treatment

参考文献/References:

1 Beral V,Million Women Study Collaborators.Breast cancer and hormone-replacement therapy in the Million Women Study.Lancet,2003,362(9382):419-427.
2 Chlebowski RT,Hendrix SL,Langer RD,et al.Influence of estrogens plus progestin on breast cancer and mammography in healthy postmenopausal women:the women’s health initiative randomized trial.J Am Med Assoc,2003,289(24):3243-3253.
3 Weihua Z,Andersson S,Cheng G,et al.Update on estrogen signaling.FEBS Letters,2003,546(1):17-24.
4 Bardin A,BouIIe N,Lazennec G,et al.Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.Endocr Relat Cancer,2004,11(3):537-551.
5 Eubank WB,Mankoff DA.Evolving role of positron emission tomography in breast cancer imaging.Semin Nucl Med,2005,35(2):84-99.
6 Linden HM,Stekhova SA,Link JM,et al.Quantitative fluoroe-stradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.J Clin Oncol,2006,24(18):2793-2799.
7 Mankoff DA,Peterson LM,Tewson TJ,et al.[18F]-fluoroestradiol radiation dosimetry in human PET studies.J Nucl Med,2001,42(4):679-684.
8 Mortimer JE,Dehdashti F,Siegel BA,et al.Metabolic flare:Indicator of hormone responsiveness in advanced breast cancer,j Clin Oncol,2001,19(11):2797-2803.
9 Yoo J,Dence CS,Sharp TL,et al.Synthesis of an estrogen receptor beta-selective radioligand:5-[18F]fluoro-(2R,3S)-2,3-bis(4-hydroxy-phenyl) pentanenitrile and comparison of in vivo distribution with 16alpha-[18F]fluoro-17beta-estradiol.J Med Chem,2005,48 (20):6366-6378.
10 Vijaykumar D,Al-Qahtani MH,Welch MJ,et al.Synthesis and biological evaluation of a fluorine-18 labeled estrogen receptor-alpha selective ligand:[18F] propyl pyrazole trioi.Nucl Med Biol,2003,30(4):397-404.
11 Aliaga A,Rousseau JA,Ouellette R,et al.Breast cancer models to study the expression of estrogen receptors with small animal PET imaging.Nucl Med Biol,2004,31(6):761-770.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
　Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[3]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
　Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[4]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
　Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[5]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
　chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[6]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
　Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[7]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[8]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
　Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[9]黄娟,颜剑豪,梁联保,等.注射钆剂后弥散加权成像对乳腺肿瘤诊断的影响[J].国际放射医学核医学杂志,2015,39(4):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
　Huang Juan,Yan Jianhao,Liang Lianbao,et al.Evaluation of the diffusion-weighted imaging after contrast for the characterization of breast tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):287.[doi:10.3760/cma.j.issn.1673-4114.2015.04.003]
[10]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
　Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[11]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
　LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[12]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
　LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[13]严惟力,黄钢.乳腺癌辐射抗性的影响因素及其可能作用[J].国际放射医学核医学杂志,2006,30(4):193.
　YAN Wei-li,HUANG Gang.Factors implicated to radioresistance of breast cancer and their possible roles[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):193.
[14]郭睿,晋建华.99mTc-depreotide生长抑素受体显像的临床应用研究[J].国际放射医学核医学杂志,2007,31(3):154.
　GUO Rui,JIN Jian-hua.The clinical application and study of 99mTc-depreotide somatostatin receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):154.
[15]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
　WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):17.

备注/Memo

备注/Memo:
收稿日期:2006-09-28。
通讯作者:孟召伟,E-mail:james-mencius@eyou.com
更新日期/Last Update: 1900-01-01